What happened: The UK and US have agreed to remove tariffs on pharmaceutical exports. In exchange, the NHS will increase the prices it pays for new drugs by 25%.
Why it matters:
- The NHS may face around £3 billion in additional drug costs over three years.
- Patients with conditions like breast cancer and asthma could benefit from greater access to innovative medicines.
MNN Take: This deal aims to boost UK pharmaceutical exports to the US while providing more funding for new drug development within the NHS budget.
Sources: Guardian UK